Other substances

Tegobuvir

A non-nucleoside inhibitor of the hepatitis C virus.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
4
 AI-suggested references
0
 Clinical trials

General information

Tegobuvir on DrugBank
Tegobuvir on PubChem

 

Structure image - Tegobuvir

C1=CC=C(C(=C1)C2=NC3=CN(C=CC3=N2)CC4=NN=C(C=C4)C5=C(C=C(C=C5)C(F)(F)F)C(F)(F)F)F

Supporting references

Link Tested on Impact factor Notes Publication date
Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2
Spike protein nsp9 Small molecule In silico 		in silico 3.22

Predicted to inhibit the SARS-CoV-2 spike protein.

 Aug/24/2020

AI-suggested references

Link Publication date
SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12)
Jul/09/2020
Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection
Sep/08/2021
Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA
May/10/2020
In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling
Feb/18/2021
Export (.csv)